Background on Amrita's Novel Science Platform



Amrita Therapeutics Senior Science Advisor and Co-Founder, Dr. Ananda Chakrabarty, has pioneered the research of protein products of bacteria useful in the body's defense against a raft of serious illnesses, and his research demonstrates that certain products of bacteria operate through multiple pathways and mechanisms to fight diseases such as cancer, malaria or HIV/AIDS.

 

Amrita's proprietary science platform addresses the need for an alternative to so-called rational drug development. Citing escalating costs and falling productivity rates, academics and other industry experts have commented on the need for effective alternatives to target-based drug discovery both in terms of combination therapies and Multiple Disease Targetting (MDT) drug development. In the area of cancer, MDT therapies may also prevent cancer cells from rapidly developing resistance to the therapy.

 

Although there has been heightened interest in bacterial biomedical research, we are not aware of any other company that is pursuing anything similar to Amrita Therapeutics (MDT) therapies and/or use of protein products from micro-organisms resident in the human body as a focus for bio-pharmaceutical drug development. To protect the proprietary nature of Amrita's novel science platform, the company has filed provisional patent applications relating to novel peptides for use as anti-cancer therapies, as well as for an innovative hybrid medical device for in situ cancer therapy.


As shown below, some of the most effective medicines target multiple symptoms or diseases:

Highly Effective MDT Drugs

Some of the most successful drugs such as Imatinib mesylate (Gleevec®) and Clozapine (Clozaril®, Leponex®, Fazaclo®) are more effective because they operate through multiple mechanisms against a number of serious diseases:

 

• Gleevec®, originally thought to be effective against chronic myeloid leukemia (CML), also works to treat gastrointestinal stromal tumors because it targets alternative kinases as well.

 

• Clozapine, a compound that has been in the market for almost 50 years (Clozaril®,

Leponex®, Fazaclo®), successfully treats schizophrenia and other central nervous system (CNS) disorders.

 

• Aspirin (acetyl salicylic acid), known not only for its activity as a pain killer but also in blood thinning and reduction of platelet aggregation for ameliorating cardiovascular problems. Aspirin also shows activity against certain forms of cancer such as colorectal or prostate cancer where cyclooxygenase-2 (COX-2) levels are high and aspirin acts as a potential COX-2 inhibitor.

 

 

Overcoming the Toxicity of Live Bacteria


Researchers have long known that many pathogenic bacteria causing human infections can attack various tumors and cause tumor regression. During their residence in human bodies, pathogenic bacteria see cancer cells as invaders, and seek to stop them in their tracks. Use of live bacteria in cancer research, however, has not been able to overcome the severe toxic effect of bacteria on the human body. This remains a challenge today and has limited the success of R&D based on use of live bacteria. Amrita Therapeutics overcomes this constraint by employing the protein products of bacteria, and not the live bacteria themselves.